Knowledge Library

OXGENE’s AAV and Lentiviral packaging plasmids are now available off-the-shelf at GMP grade globally

Resource Type: Poster
Resource Topic: Clinical & Commercial Manufacturing

VIEW

Analytical Ultracentrifugation for Profiling AAV Gene Therapies

Adenoassociated virus (AAV) is often the vector of choice for gene therapies due to their low immunogenicity, ability to promote long-term gene expression, and capsid tropism-dependent tissue specificity. Representing around 37% of the current advanced therapies market, there is an ongoing demand for robust quality lot release programs capable of supporting the large patient cohorts …Read More >

Resource Type: Webinar
Resource Topic: Advanced Testing

VIEW

TiCARos Therapeutics Case Study – Accelerating the development of advanced therapies from discovery to biomanufacture

TiCARos Therapeutics has leveraged the expertise of their team of immunologists from Seoul National University, College of Medicine to develop a promising pipeline of nextgeneration immunotherapies for intractable haematologic malignancies and advanced solid tumours. TiCARos’ mission is to create medication based on science. TiCARos was founded by two leading T cell immunologists, who have built …Read More >

Resource Type: Case Study
Resource Topic: Clinical & Commercial Manufacturing

VIEW

WuXi Advanced Therapies Testing Facility & Virtual Tour

New state-of-the-art advanced therapies testing laboratories provide additional capacity for the growing cell and gene therapy industry. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, has opened its advanced therapies testing facility at 400 Rouse Boulevard in Philadelphia’s Navy Yard. The new facility, which includes 140,000 square feet laboratories, will further …Read More >

Resource Type: Video
Resource Topic: Advanced Testing

VIEW

Improve and Innovate – Next Generation AAV Manufacturing Strategies

Adeno-associated virus (AAV) is often the vector of choice for gene therapies; in fact, AAV represents around 37% of the current advanced therapies market. And when it comes to manufacturing AAV for in vivo gene therapies, developers must pursue triplicate goals of quality, quantity, and speed. At OXGENE and WuXi ATU, our ambition is to …Read More >

Resource Type: Webinar
Resource Topic: Clinical & Commercial Manufacturing

VIEW